Abstract Effective biomedical and structural HIV prevention approaches are being implemented throughout sub-Saharan Africa. A "lifecycle approach" to HIV prevention recognizes the interconnectedness of the health of women, children and adolescents, and prioritizes interventions that have benefits across these populations. We review new biomedical prevention strategies for women, adolescents and children, structural prevention approaches, and new modalities for eliminating infant HIV infection, and discuss the implications of a lifecycle approach for the success of these methods.
Introduction
HIV/AIDS disproportionately afflicts women in Africa. Thus, HIV prevention efforts which focus on women are critical to decreasing the AIDS epidemic in this region. Further, the health of women has a substantial impact on household and child health, making women's health essential for improving the health of populations. The past several years have yielded major advances in preventing HIV among women and children. Here, we review these advances and then explore how an integrated "lifecycle" approach to HIV prevention and treatment has potential to limit the HIV epidemic and provide broader benefits for global health.
The Lifecycle Approach: New Opportunities in HIV Prevention/Treatment for Women and Children
Conventional approaches to medical care and research have viewed women, children, and adolescents as three distinct populations; formal specialties and sub-specialties exist to treat these three patient populations in separate silos with little overlap between disciplines. However, infant health is inextricably tied to maternal health, and childhood and adolescent health have long-term implications for future mothers. In this way, these three stages of a woman's life can be seen as part of an interconnected "lifecycle" (Fig. 1) . Health risks at any one of these stages have broader effects on the lifecycle as a whole; similarly each stage represents a unique opportunity to introduce interventions that have broader benefits across these three stages. A "lifecycle approach" thus recognizes the interconnectedness of women, children and adolescents, and prioritizes interventions that have benefits across these populations. Activities which integrate multiple health interventions, such as breastfeeding and family planning, have especially farreaching benefits across the lifecycle and the community. The lifecycle approach presents new opportunities to engage women and children in coordinated care that integrates HIV/AIDS prevention and care into optimal and proven health interventions at established entry points to the health care system.
Using the lifecycle approach, we have identified several key interventions at different time points for not only preventing HIV but also enhancing the basic health of women, adolescents and children. It is possible to work synergistically with HIV prevention and treatment programs to create broader health benefits for women and children ( Table 1) . Most of these lifecycle interventions also address Millennium Development Goals, demonstrating the high impact of these interventions [1] .
HIV Prevention Strategies for Women and Adolescents are Evolving
Multiple randomized controlled trials have provided evidence for new effective antiretroviral prevention methods among sexually active women. The HPTN 052 randomized controlled trial showed that in heterosexual discordant couples, treatment of one partner with antiretroviral therapy (ART) reduced risk of HIV transmission within the couple by 96 %, although partners remained at risk of acquiring HIV Fig. 1 The maternal, infant and adolescent lifecycle, and associated health interventions from outside their relationship [2] . Pre-exposure prophylaxis with daily tenofovir or tenofovir-emtricitabine in HIVdiscordant couples resulted in a 60 and 75 % reduction in HIV acquisition by the HIV-negative partner, and was shown to be effective at protecting both men and women in serodiscordant relationships [3] . The TDF2 study in Botswana demonstrated 62 % effectiveness of tenofovir-emtricitabine at protecting individuals at risk of heterosexual acquisition of HIV [4] . The CAPRISA 004 study showed that pericoital application of 1 % tenofovir vaginal gel by African women resulted in a 39 % reduction in HIV-1 acquisition [5] , although these results were not replicated by the VOICE trial (described below) [6] . These diverse antiretroviral interventions for HIV prevention represent a major advance in biomedical strategies to protect women.
Despite these successes in preventing HIV transmission among older, married women, the crisis among adolescent females in Africa remains sobering, with adolescent females (ages 15-24) infected with HIVat twice the rates of adolescent males. Staggeringly high HIV-1 incidence rates of 8.8 % per year were noted in unmarried women <25 years of age participating in the VOICE study [6] ; in the CAPRISA study, a site in South Africa noted HIV a prevalence among girls ages 14-17 of 27.6 % [7] . Effective methods to target adolescent women are urgently needed, and this demographic disparity drives the epidemic in both women and children. Unfortunately, in two trials focusing on women-controlled methods, pre-exposure prophylaxis was ineffective. In the FEM-PrEP trial, pre-exposure prophylaxis with oral tenofovir failed to protect young, single women [8] , with poor adherence the Co-infection prevention and treatment (including malaria, parasitic infections, enteric infections)
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Chronic disease screening/treatment • Reduce maternal morbidity and mortality MDG 2, 3, 7 MTCT = mother to child transmission. HIV = human immunodeficiency virus. MDG = millennium development goal primary cause for the lack of effectiveness seen. Similarly, in the VOICE study, among a population of young, high-risk women in sub-Saharan Africa, oral tenofovir and tenofovir vaginal gel were ineffective [6] . The failure of these trials underscores challenges of prevention methods that require persistent adherence by users. New women-controlled topical prevention methods under investigation, including the dapivirine ring, and development of combination products that can prevent HIV, STIs and pregnancy may circumvent these adherence challenges, which are particularly critical for adolescent populations [9] . Male circumcision is an effective HIV prevention intervention for adult and adolescent males [10] [11] [12] and contributes to population-level reductions in HIV prevalence [13•] . Demand for services are high among young men and boys, and in one country (Kenya) this demand has led to a minimum age for circumcision [14] . Some countries are still struggling to promote circumcision among adult men, but in the long-term, circumcision is an HIV prevention intervention which can be specifically targeted to male adolescents. Finding more effective ways to reach male and female adolescent populations in the lifecycle will be a major advance in HIV prevention.
Structural Interventions for HIV Prevention in Women and Adolescents May Complement Biomedical Advances
Given the complexity and differential benefit of biomedical prevention methods, sociobehavioral and structural interventions have been studied including education and conditional cash transfers (CCT) [15] [16] [17] 18 •] as ways to prevent HIV among young women. Higher educational attainment is associated with better health outcomes for women both short-term and long-term, and results in better child health. A pilot intervention that focused on keeping adolescent women in school by paying school fees successfully delayed sexual debut and reduced HIV infection in a low-prevalence setting, resulting in 3 % infected in the control arm and 1.2 % infected in the intervention arm [16] . A randomized controlled trial of CCT to reduce adolescent vulnerability also showed modest reductions in HIV seroconversion among adolescents [19] . The results from these trials show that broader poverty reduction strategies may have beneficial impacts on adolescent and women's HIV risk [20] .
A recent article reviewed diverse efforts to address the social and structural drivers of the HIV epidemic, including transforming gender norms, reducing violence, transforming legal norms, promoting education, promoting employment, and reducing stigma and discrimination [21] . Many of these efforts are effective or promising at preventing HIV among women and girls. Structural interventions across the lifecycle should be implemented in conjunction with biomedical strategies to reduce HIV infection.
Prevention of HIV in Infants Yields Concurrent Impact on Mothers with HIV
World Health Organization (WHO) recommendations for the prevention and treatment of HIV infection in women and infants recognize and incorporate a lifecycle approach in their most recent iteration [22••] . Recommendations to promote Option B (triple antiretroviral therapy during pregnancy and breastfeeding) or Option B+ (triple antiretroviral therapy started in pregnancy and continued for life) optimize risk reduction for the infant while simultaneously addressing the health needs of the mother. Shifting to Option B/B+ helps address significant health systems bottlenecks, including difficulties deploying CD4 counts in rural areas and assuring timely receipt of CD4 count results [23, 24•, 25] . These recommendations also incorporate the preponderance of evidence indicating that HIV positive women in resource-limited settings should breastfeed for optimal infant health and survival [26] [27] [28] [29] . In addition, most women currently receiving short-course ART would soon become eligible for ART within a few years of pregnancy [30] , and Option B+ also protects women and infants during later intended or unintended pregnancies. The widespread implementation of ART starting in pregnancy in Malawi resulted in an over seven-fold increase in women initiating ART over one year [31] . This approach is being implemented in Africa but is not yet widespread. A recent review attributed 24 % of maternal mortality in Africa to HIV [32••] . Option B+ offers operational advantages, and may yield improvements in women's health [33] , reductions in maternal mortality, as well as reduction in transmission to uninfected male partners.
Momentum in Elimination of MTCT Offers New Opportunities to Enhance Health of Women, Adolescents and Children
Elimination of pediatric HIV has taken center stage as a multipronged public health strategy. The four pillars of the pediatric HIV elimination strategy are: prevention of maternal HIV infection, family planning to prevent unwanted pregnancies, antiretroviral therapy in pregnancy, delivery and breastfeeding, and provision of care and treatment to all HIV-infected women, children, and families [34] . All of these strategies rely on an integrated, lifecycle approach to family health.
Through expansion of maternal HIV testing and shortcourse antiretroviral regimens, pediatric HIV infections have been reduced by 50 % since 2001. In 2012 it was estimated that 260,000 children acquired HIV. However, the 2013 UNAIDS report outlines disparity in access to the most basic PMTCT services. In Africa, 13 countries reach fewer than 50 % of women with PMTCT services, including Nigeria, the most populous country in Africa, and a further ten countries reach fewer than 75 % of women with even basic PMTCT services [35] . Antiretroviral coverage for breastfeeding women lags further behind, with only 49 % of women protecting breastfeeding infants by using antiretroviral therapy or prophylaxis. Consequently, the incidence of HIV acquired during breastfeeding is beginning to account for a larger proportion of pediatric HIV infections. To achieve a target of elimination of pediatric HIV, these missed opportunities need to be comprehensively addressed. Integrating HIV prevention for children into the events of a child's lifecycle, such as immunization and pediatric nutrition, could be a way to ensure that pediatric HIV prevention strategies are fully implemented.
For optimal infant survival, early infant diagnosis is a key intervention for HIV-exposed children, but significant barriers remain to diagnosing infants early in their lives. The CHER study showed that early infant diagnosis and prompt initiation of ART resulted in a fourfold decrease in mortality [36] . Further, HIV-exposed infants who are followed have improved growth and survival [37] . However, despite the fact that African infants receive immunizations and are therefore accessing health care, a majority of HIV-exposed infants are not followed after mothers deliver, and do not get the full benefit of early diagnosis and referral to treatment [24•, 38] . Quality improvement projects aimed at linking mothers from PMTCT programs with early infant diagnosis services have been piloted [39] , but most programs remain far from the goal of testing all HIV-exposed infants [40] . Stronger integration of PMTCT and maternal, newborn and child health services are needed to fully address this gap [41, 42] .
In 2013, UNAIDS estimates that there are 17.8 million orphan children who have lost one or both parents in 2013 [43] , and research suggests that orphans remain incredibly vulnerable to morbidity, mortality, exploitation, and acquisition of HIV [44, 45] . This information underscores the links between maternal survival and infant health, and lends urgency to efforts to eliminate mother-to-child transmission and also to implement Option B+ to optimize maternal survival and health. In addition, a lifecycle approach which improves overall child health may mitigate some of the additional vulnerability among orphans.
HIV Prevention for Women and Children during Pregnancy, Lactation, and Contraception Must be Enhanced
HIV prevention methods in women, and improvement in access and integration of family planning services in HIV care are part of the pediatric HIV elimination agenda, however neither is well-integrated into traditional programs for PMTCT. Addressing these time points in a woman's lifecycle with comprehensive HIV prevention services would augment efforts to eliminate pediatric HIV.
Primary prevention of HIV in women, including prevention methods reviewed above (biomedical prevention such as ART in partners, pre-exposure prophylaxis, topical ART, adolescent HIV prevention, male circumcision) all have beneficial downstream effects for a woman and her children, and are an important and often overlooked pathway to eliminate pediatric HIV. Increasing attention has been focused on pregnancy as a high-risk time for HIV acquisition [46] [47] [48] and subsequent transmission to infants; HIVacquisition during the two years of lactation also places an infant at high risk [49] . Current PMTCT programs offer little to HIV negative women after initial screening during antenatal care and may not be adequately reaching women at risk for HIV infection during pregnancy and lactation. As PMTCT programs expand, the proportion of HIV infected infants who acquire their infection due to acute maternal infection will increase. HIV preventive interventions such as PrEP have not been evaluated for use in pregnant or lactating women, in part due to ethical concerns about fetal and infant exposure. Because fertility rates are high in Africa, many HIV uninfected women have substantial periods in which they are either pregnant or breastfeeding, and it will be critical to identify HIV preventive options for these periods.
Family planning access has been improving since 1990: worldwide contraceptive prevalence from 1990 to 2010 increased from 55 to 64 % of married women having ever used family planning, and "unmet need" for family planning decreased from 15 to 12 % [50] . However, in sub-Saharan Africa, where HIV infection is highly prevalent among women, contraceptive use is lower. Use among married women in Southern Africa is estimated at 60 %, about 35 % for Eastern Africa, but lower than 20 % for both Central and West Africa. Using methods that include all fecund women, Darroch et al. estimated that in 2012 there were 59 million women in Africa with unmet need for modern contraception and that a majority (53 %) of women wanting to use contraception had no access to modern methods [51•] . Recent attention to possible risks of enhanced HIV acquisition and transmission among users of depot-medroxyprogesterone acetate (DMPA) [52] [53] [54] are concerning, but the controversy surrounding DMPA use has highlighted both the reproductive health imperatives of access to safe contraception, and the limited contraceptive options currently available and acceptable to African women. Among HIV-positive African women, unmet need for contraception remains high, even among women who are accessing HIVrelated services [55] [56] [57] [58] . Studies of integration of family planning clinics into HIV services have shown that integration may improve uptake among HIV positive women [59] [60] [61] . Further progress in expanding access to diversified family planning methods remains an unfulfilled opportunity to improve the health of all women, and represents an opportunity to make further progress on the elimination of MTCT agenda [62] .
Challenges to Implementation of the Lifecycle Approach
Integration of HIV prevention into health care delivery services is a goal of 90 % of countries surveyed by UNAIDS in 2012 [35] . To have maximum impact, the package of highly effective HIV prevention methods reviewed in this article will need to be integrated into every aspect of the health sector. However, currently HIV interventions are largely considered separate from other health interventions in the lifecycle. The women-adolescent-child lifecycle acts as a framework for building a program to meet these different health goals, and builds on the history of integration of PMTCT services with maternal and child health care. The additional resources and training for PMTCT efforts have brought needed resources to the larger MCH clinical setting. Similarly, implementing a broader and more comprehensive agenda of lifecycle-based HIV prevention into health services could strengthen the health system. Some examples of relatively simple lifecycle approaches with large dividends include expanding access to family planning for all women in an integrated fashion, which benefits HIV positive women and promotes elimination of mother-tochild transmission, but also benefits HIV negative women and improves their health status. Integrating male circumcision into child and adolescent health programs will reach more people while also strengthening health services for those age groups. Promotion of exclusive breastfeeding can be implemented as a child health intervention as well as an HIV prevention intervention. More complicated lifecycle approaches could include more diverse public health efforts, including improving water and sanitation, malaria prevention in children and pregnant women, and routine deworming, which both provide immediate health benefits and also synergistic downstream benefits to women and children later in the lifecycle.
In addition, the lifecycle approach can unify sectors beyond health care by outlining the health benefits from different interventions. For example, support for early childhood education, support for domestic violence prevention initiatives, and support for women's legal aid all can build on a lifecycle framework which demonstrates the benefits of integrating around the goal of improving women's and children's health and well-being. Several recent articles have described the strengths and synergies of combination prevention approaches in HIV. Chang et al. discussed the potential benefits of pragmatic "combination implementation." This involves simultaneous implementation of multiple proven HIV prevention strategies to maximize population level effects to affect the HIV epidemic [63] . Vermund and Hayes reviewed the transmission benefits of synergistically applying behavioral, structural and biomedical prevention approaches to reduce HIV viral load and therefore reduce onward viral transmission, creating a "package" of interventions similar to current multipronged approaches in malaria and tuberculosis control [64] . Similarly, Allsallaq and others modeled the potential benefits of synergistic implementation of multiple prevention interventions in a hyperendemic community in South Africa to arrest the HIV epidemic, finding reductions in HIV incidence from 47-63 % within 4 years when interventions overlapped [65] . These strategies are focused on maximizing the impacts of the interventions on the HIV/AIDS epidemic. However, a lifecycle approach would expand the scope of the intervention and would include other health objectives outside of HIV/AIDS. The "diagonal approach" to maternal and child health (MCH) outlined by Gounder et al. [66] describes using a scaffolding of HIV/AIDS and MCH programs to build multiple health intervention programs for women. The lifecycle approach similarly is woman-focused and allows each time point in a woman's life to implement HIV prevention efforts and other health interventions, with a goal of both preventing HIV and improving woman, adolescent and child health and wellbeing. In this era of static investment in HIV programming, the lifecycle approach maximizes scarce resources by expanding beneficial health interventions out of the HIV silo.
Conclusions
More than ever before, HIV prevention in women, and elimination of pediatric HIV, are tangible goals that will substantially improve the lives of women and children in countries highly affected by HIV. A lifecycle approach provides added efficiency in HIV prevention, and may additionally confer broader benefits across populations. Lifecycle interventions may thus provide an attractive framework for implementation of HIV prevention methods at scale to improve health and well-being of communities. Investments in a lifecycle approach will be a lasting contribution to health care infrastructure beyond the HIV pandemic.
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